Scopolamine Market Size (2024 - 2029)

The scopolamine market is anticipated to experience growth over the forecast period, driven by an increase in surgical procedures and ongoing research into its therapeutic applications. The market's expansion was initially hindered by the COVID-19 pandemic, which reduced surgical volumes and, consequently, the demand for scopolamine. However, the market has since recovered as surgical activities resumed. Factors such as rising healthcare expenditure and the drug's adaptation for various treatments, including its use in managing depression, are expected to further support market growth. Despite these positive trends, challenges such as potential side effects, misuse, and stringent regulatory policies may impede the market's progress.

Market Size of Scopolamine Industry

Scopolamine Market Summary
Study Period 2021 - 2029
Base Year For Estimation 2023
CAGR 6.10 %
Fastest Growing Market Asia-Pacific
Largest Market North America
Market Concentration Medium

Major Players

Scopolamine Market Major Players

*Disclaimer: Major Players sorted in no particular order

Scopolamine Market Analysis

Over the next few years, the scopolamine market is expected to register a CAGR of about 6.1%.

The COVID-19 pandemic had an extraordinary impact on the scopolamine business. Scopolamine was mostly employed in surgical procedures, and the fall in surgical volume during the pandemic hampered the scopolamine market's growth. For instance, according to an article published in Jama Network in April 2021, an article reported that the frequency of surgical procedures throughout the country experienced a substantial decrease that may persist after the COVID-19 pandemic's initial exponential growth phase. Thus, the surgical procedures were reduced, which decreased the need for scopolamine-related dosage forms as it is used to prevent nausea and vomiting after anesthesia, narcotic pain medicines, and surgery. Thus, initially, the market was severely impacted, but after a few months, it gained its momentum for growth. Over the last two years, the market recovery has been led by the rise in several surgical procedures. For instance, as per the January 2022 report from Euractiv, during the pandemic, 400,000 surgeries were postponed, which considerably increased the number of patients on the waiting list. During the projected period, the market is predicted to have a significant increase in surgeries, which is expected to support market growth in the following years.

The factors that may drive the market are the growing number of surgical procedures, rising healthcare expenditure, and adaptation to scopolamine. According to a July 2021 article published in the Annals of Surgery, nearly nine major surgeries were performed annually in the United States for every 100 older people, and more than one in every seven Medicare beneficiaries underwent a major surgery over five years, representing nearly 5 million surgeries in the United States each year.Thus, a significant number of surgical procedures are performed annually, and it is expected to raise demand for scopolamine to help reduce secretion during surgical operations, thereby boosting the market's growth.

Also, growing treatment trials on scopolamine and its increasing use for the treatment of various diseases In recent times, many studies have reported the use of scopolamine in the treatment of major depressive disorder. For instance, in April 2021, an article published in the International Journal of Psychiatry reported that most available treatment trials of scopolamine have confirmed the rapid onset of antidepressant effects in unipolar and bipolar depression and that scopolamine is used as an alternative treatment option to ketamine in patients with treatment-resistant depression. In addition, the article also reported that seven treatment trials have demonstrated the rapid therapeutic effects of scopolamine in depression, both as monotherapy and as augmentation. Similarly, in August 2022, Southwest Research Institute developed an efficient, fully synthetic method to produce scopolamine, a plant-derived compound used to prevent nausea and vomiting from motion sickness and anesthesia. The accomplishment marks the first time SwRI has fully synthesized a drug compound that is naturally derived from plants. Thus, such research and clinical studies are driving the scopolamine market.

Thus, owing to the above-mentioned factors, such as an increase in the number of surgical procedures and research activities on scopolamine, it is expected to boost the scopolamine market's growth over the forecast period. However, side effects and misuse of scopolamine, and stringent regulatory policies, may slow down its growth during the studied period.

Scopolamine Industry Segmentation

As per the scope of the report, scopolamine is an anticholinergic agent that is used to reduce the secretions of certain organs. It is used in the treatment of motion sickness and postoperative nausea and vomiting. It is sometimes also used before the surgery to decrease secretions such as saliva. The scopolamine market is segmented by dosage form (injectables, tablets, transdermal patches, and others), distribution channel (hospital pharmacies, retail pharmacies, and others), and geography (North America, Europe, Asia-Pacific, the Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Dosage Form
Injectables
Tablets
Transdermal Patches
Other Dosage Forms
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Other Distribution Channels
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Scopolamine Market Size Summary

The scopolamine market is poised for growth, driven by an increase in surgical procedures and advancements in medical research. Initially impacted by the COVID-19 pandemic, which led to a reduction in surgical volumes and, consequently, a decline in scopolamine demand, the market has since rebounded. The resurgence in surgical activities, coupled with rising healthcare expenditures, is expected to bolster the market. Scopolamine's application in preventing nausea and vomiting post-anesthesia and its emerging role in treating conditions like major depressive disorder further contribute to its market expansion. The development of synthetic methods for producing scopolamine and ongoing clinical trials underscore its therapeutic potential, enhancing its adoption across various medical fields.

The transdermal patch segment, in particular, is anticipated to experience significant growth due to its ease of use and effectiveness in treating motion sickness. The increasing number of surgeries, especially in regions like North America, where healthcare infrastructure is robust, is expected to drive demand for scopolamine patches. Regulatory approvals, such as those from the U.S. Food and Drug Administration, and the rising incidence of cancer-related surgeries further support market growth. The competitive landscape is characterized by the presence of both global and regional players, with companies like Pfizer Inc. and Baxter International Inc. holding substantial market shares. Overall, the scopolamine market is set to expand, supported by technological advancements, regulatory developments, and a growing patient base requiring surgical interventions.

Explore More

Scopolamine Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Growing Number of Surgical Procedures due to Chronic Diseases

      2. 1.2.2 Rising Healthcare Expenditure and Adaptation of Scopolamine

    3. 1.3 Market Restraints

      1. 1.3.1 Side Effects and Misuse of Scopolamine

      2. 1.3.2 Stringent Regulatory Policies

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 2.1 By Dosage Form

      1. 2.1.1 Injectables

      2. 2.1.2 Tablets

      3. 2.1.3 Transdermal Patches

      4. 2.1.4 Other Dosage Forms

    2. 2.2 By Distribution Channel

      1. 2.2.1 Hospital Pharmacies

      2. 2.2.2 Retail Pharmacies

      3. 2.2.3 Other Distribution Channels

    3. 2.3 Geography

      1. 2.3.1 North America

        1. 2.3.1.1 United States

        2. 2.3.1.2 Canada

        3. 2.3.1.3 Mexico

      2. 2.3.2 Europe

        1. 2.3.2.1 Germany

        2. 2.3.2.2 United Kingdom

        3. 2.3.2.3 France

        4. 2.3.2.4 Italy

        5. 2.3.2.5 Spain

        6. 2.3.2.6 Rest of Europe

      3. 2.3.3 Asia-Pacific

        1. 2.3.3.1 China

        2. 2.3.3.2 Japan

        3. 2.3.3.3 India

        4. 2.3.3.4 Australia

        5. 2.3.3.5 South Korea

        6. 2.3.3.6 Rest of Asia-Pacific

      4. 2.3.4 Middle East and Africa

        1. 2.3.4.1 GCC

        2. 2.3.4.2 South Africa

        3. 2.3.4.3 Rest of Middle East and Africa

      5. 2.3.5 South America

        1. 2.3.5.1 Brazil

        2. 2.3.5.2 Argentina

        3. 2.3.5.3 Rest of South America

Scopolamine Market Size FAQs

The Scopolamine Market is projected to register a CAGR of 6.10% during the forecast period (2024-2029)

Pfizer Inc., Baxter International Inc., Myungmoon Pharm Co Ltd, Caleb Pharmaceuticals, Inc. and C2 Pharma (Centroflora-Cms) are the major companies operating in the Scopolamine Market.

Scopolamine Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)